Finance

Lists
Why is SGIOY up 3,65%?
Dive Deeper
SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
US$9,09
+3,65%
(+0,32) 1D
15 ຕ.ລ., 10 ໂມງ 47 ນາທີ 51 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SGIOY...
Open
US$9,53
High
US$9,53
Low
US$8,95
Mkt. cap
2,58 ລ້ານລ້ານ
Avg. vol.
172,76 ພັນ
Volume
17,13 ພັນ
52-wk high
US$12,00
52-wk low
US$7,83
Beta
0,07
Shares outstanding
1,78 ຕື້
No. of employees
6 ພັນ
Open
US$9,53
High
US$9,53
Low
US$8,95
Mkt. cap
2,58 ລ້ານລ້ານ
Avg. vol.
172,76 ພັນ
Volume
17,13 ພັນ
52-wk high
US$12,00
52-wk low
US$7,83
Beta
0,07
Shares outstanding
1,78 ຕື້
No. of employees
6 ພັນ
News stories
From web sources and news partners
Yahoo Finance
Yahoo Finance
·
1 ມື້ກ່ອນ
SGIOY or UTHR: Which Is the Better Value Stock Right Now?
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
About Shionogi 2 ADR Representing 1 Ord Shs
CEOIsao Teshirogi
Employees6,22 ພັນ
Founded1878
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
113,18 ຕື້
147,72 ຕື້
138,99 ຕື້
163,31 ຕື້
Cost of goods sold
16,94 ຕື້
25,09 ຕື້
28,10 ຕື້
30,80 ຕື້
Cost of revenue
16,94 ຕື້
25,09 ຕື້
28,10 ຕື້
30,80 ຕື້
Research and development expenses
27,55 ຕື້
29,87 ຕື້
40,54 ຕື້
31,79 ຕື້
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27,56 ຕື້
35,27 ຕື້
32,92 ຕື້
44,36 ຕື້
Operating expense
56,57 ຕື້
48,45 ຕື້
100,06 ຕື້
113,87 ຕື້
Total operating expenses
73,51 ຕື້
73,54 ຕື້
128,17 ຕື້
144,66 ຕື້
Operating income
39,67 ຕື້
74,18 ຕື້
10,83 ຕື້
18,64 ຕື້
Other non operating income
-
-1,00 ລ້ານ
7,31 ຕື້
-2,00 ລ້ານ
EBT including unusual items
52,06 ຕື້
92,89 ຕື້
47,64 ຕື້
73,74 ຕື້
EBT excluding unusual items
52,06 ຕື້
93,10 ຕື້
47,80 ຕື້
25,47 ຕື້
Income tax expense
7,87 ຕື້
18,21 ຕື້
-56,00 ລ້ານ
-23,98 ຕື້
Effective tax rate
15,12%
19,60%
-0,12%
-32,52%
Other operating expenses
979,00 ລ້ານ
-17,25 ຕື້
15,44 ຕື້
21,90 ຕື້
Net income
44,19 ຕື້
74,68 ຕື້
46,93 ຕື້
97,70 ຕື້
Net profit margin
39,04%
50,56%
33,77%
59,82%
Earnings per share
-
-
-
-
Interest and investment income
14,21 ຕື້
20,53 ຕື້
23,73 ຕື້
12,15 ຕື້
Interest expense
-1,82 ຕື້
-1,61 ຕື້
-
-5,32 ຕື້
Net interest expenses
12,38 ຕື້
18,92 ຕື້
23,73 ຕື້
6,82 ຕື້
Depreciation and amortization charges
-485,00 ລ້ານ
-
-1,53 ຕື້
-
EBITDA
44,83 ຕື້
80,21 ຕື້
21,59 ຕື້
39,52 ຕື້
Gain or loss from assets sale
-
-
35,04 ຕື້
-
AI content may include mistakes. Learn more
ແອັບຂອງ Google